Not yet recruiting NCT07337967
Reticulocyte Parameters as Early Indicators of Bone Marrow Erythropoietic Activity in Chronic B Lymphoproliferative Neoplasms
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: B Chronic Lymphocytic Leukemia. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
Reticulocyte parameters as early indicators of bone marrow erythropoietic activity in chronic B lymphoproliferative neoplasms
Primary outcome measures
- Reticulocyte count [Time frame: 1 year]
- Reticulocyte percentage [Time frame: 1 year]
- Immature reticulocyte fraction (IRF) [Time frame: 1 year]
Eligibility criteria
Inclusion criteria
\- Newly diagnosed adult patients with Chronic B LymphoPoliferative neoplasm according to WHO classification.
Exclusion criteria
1\) Patients received chemotherapy.
- Patients with Active bleeding
- Patients with recent blood transfusion (less than 2 weeks).
- Patients on haematinics or vitamin B 12 therapy
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Other
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT07337967 · AUN-FOM-CP-CLPD-RETIC-2025